AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04384731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poractant alfa
Description: Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
Study NCT01123018 — intervention group
Intervention type: BEHAVIORAL
Intervention: Memtrax Memory screening test
Description: Memory Screening test
Study NCT03713567 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimentally induced plaque
Description: Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
Study NCT03713567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimentally induced plaque
Description: Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
Study NCT04413318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic device (VBM©)
Description: Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
Study NCT04413318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic device (Nosten©)
Description: Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
Study NCT02866578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open lung protective ventilation strategy
Study NCT00672880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-System Therapy
Description: 12 sessions of structured Self-System Therapy
Study NCT00672880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 12 sessions of spine and muscle education including life style changes and medical treatments.
Study NCT01461967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending doses
Study NCT04592731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel containing Acetylated Natural Nucleotides
Description: The study drug is a gel containing acetylated natural nucleotides.
Study NCT04592731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
Study NCT01064830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical cyclosporine ophthalmic suspension 0.05%
Description: apply 2 drops to 2 target fingernails under occlusion daily
Study NCT01064830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
Study NCT00792818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuma domestica extracts
Description: 1,500 mg per day (oral)divided into 3 times for 28 days
Study NCT00792818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 1,200 mg/days (oral) divided into 3 times for 28 days
Study NCT02606370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable shoe
Description: Wearing Unstable shoes during 1 month
Study NCT02783508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Meperidine
Description: Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered.
Study NCT02783508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered.
Study NCT03356769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
Study NCT03356769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AED
Description: maintain the dosages and the drugs throughout the 3-month observation time
Study NCT03356769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AED
Description: maintain the dosages and the drugs throughout the 3-month observation time
Study NCT03356769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 5mg/Kg/d, once every day, 25mg per tablets
Study NCT02805673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathy
Study NCT00399919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: 2 grams per day for six months
Study NCT00399919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propionyl-L-Carnitine
Description: 2 grams per day for six months
Study NCT00399919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: 2 grams/day for six months
Study NCT00399919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLC
Description: 2 grams/day for six months
Study NCT02519582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: 2 g per day orally
Study NCT03872622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire
Description: Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
Study NCT00792675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise training
Description: Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
Study NCT02958774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
Study NCT00559975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subunit influenza vaccine
Description: 0.5 mL single dose vaccine
Study NCT00559975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted influenza vaccine
Description: 0.5 mL single dose vaccine
Study NCT00559975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine combined with CpG7909
Description: 0.5 ml influenza vaccine combined with 10 mcg of CpG7909
Study NCT00559975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine combine with CpG7909
Description: 0.5 mL single dose vaccine combined with 30 mcg of CpG7909
Study NCT00559975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine combine with CpG7909
Description: 0.5 mL single dose vaccine combined with 100 mcg of CpG7909
Study NCT03257137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Quality
Description: Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
Study NCT02367781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
Study NCT00701558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg po daily
Study NCT00701558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
Study NCT01461967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Single ascending doses
Study NCT01461967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Single doses
Study NCT00672880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Study participants continue with their usual medical care, no changes.
Study NCT01099995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
Study NCT01099995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
Study NCT02398500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMG324
Description: IVT injection
Study NCT02398500 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg
Description: IVT injection
Study NCT02398500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sham
Description: Fake injection used for masking purposes
Study NCT02398500 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Fake injection used for masking purposes
Study NCT02602288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ask, Advise, Refer
Description: WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
Study NCT02602288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask, Advise, Refer
Description: WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
Study NCT02602288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telebased tobacco counseling
Description: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
Study NCT02602288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telebased nutrition counseling
Description: Telephone counseling to promote nutritious eating practices in the family.
Study NCT02602288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone smoking cessation application
Description: Smartphone based application to support smoking cessation efforts
Study NCT02602288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone nutrition application
Description: Smartphone based application to support healthy eating habits
Study NCT02602288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Over the counter nicotine replacement therapy in gum or lozenge form.
Study NCT02376049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus cream
Study NCT02376049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate cream
Study NCT02376049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate cream
Study NCT02376049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glaxal Base cream vehicle
Study NCT02086591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study NCT01595516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks
Study NCT01595516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks
Study NCT01595516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks
Study NCT01595516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks
Study NCT01595516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks
Study NCT01595516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks
Study NCT01595516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bradykinin
Description: Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
Study NCT01595516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
Study NCT01595516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin C
Description: The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
Study NCT00612066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Study NCT01189994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needling of acupoints, some of them receiving electrostimulation
Study NCT01189994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation
Description: Orientation sessions focusing in fibromyalgia
Study NCT04527263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of urinary 5-HIAA
Description: urinary assessment of 5-HIAA
Study NCT00789217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate skin test
Description: Intradermal test with immediate reading
Study NCT03830333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
Study NCT03830333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline by IV infusion every 8 hours for 4 to 14 days.
Study NCT02609126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-104IAR
Description: Single, ultrasound-guided injection of EP-104IAR into the knee
Study NCT02609126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single, ultrasound-guided injection of vehicle placebo into the knee
Study NCT01973829 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)
Description: This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
Study NCT02934139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR
Study NCT04454957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastering Diabetes
Description: Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
Study NCT01607866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadrant parotidectomy
Description: Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
Study NCT02934139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT01010581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC12267 (4SC-101)
Description: oral administration
Study NCT01010581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT02147977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement: n-3 PUFA
Study NCT04636463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Music
Description: Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
Study NCT01090856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-dilation side branch
Description: Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
Study NCT01010581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: oral administration
Study NCT01010581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral administration
Study NCT01010581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: oral administration
Study NCT01010581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: oral administration
Study NCT04255862 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bimekizumab
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Study NCT00605384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Tenofovir
Description: Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
Study NCT04255862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Study NCT00605384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir + continuing Lamivudine
Description: Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks